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Michael C. Christensen, MSc, MPA, DrPH,a Stephan Krapf, MD,b Angela Kempel, MSc,c and
Christian von Heymann, MD, PhD, DEAAd
Background: Excessive postoperative hemorrhage in cardiac surgery is a serious clinical complication placing
substantial demands on hospital resources. This study quantifies the exact impact of postoperative hemorrhage on
hospital costs in Germany.
Methods: We retrospectively analyzed data collected prospectively in the Quality Assurance Database at the
Heart Center of the Klinikum Augsburg, Germany. All relevant perioperative data for resources consumption
were analyzed and compared in patients with and without excessive postoperative hemorrhage in cardiac surgery.
Multivariate regression analysis identified the incremental costs of postoperative hemorrhage while adjusting for
potential confounding.
Results: A total of 1118 patients had cardiac surgery between January and December 2006. Six percent were iden-
tified with excessive postoperative hemorrhage. The risk of experiencing a postoperative complication (including
death) (P<.0001), returning to operating room for reexploration (P<.0001), staying in intensive care unit for longer
than 72 hours (P<.0001), receiving ventilation for longer than 24 hours (P<.0001), and receiving any kind of post-
operative blood transfusion (P<.0001)was significantlyhigher inpatientswith excessive postoperative hemorrhage.
Twenty-two percent of patients with excessive postoperative hemorrhage died compared with 6% of the patients
without excessive postoperative hemorrhage (P< .0001). When adjusting for potential confounding factors, the
incremental costs of excessive postoperative hemorrhage was V6251 (95% confidence interval, 4594–7909).
Conclusions: The average hospital costs related to excessive postoperative hemorrhage in cardiac surgery in
Germany are substantial and associated with a significant risk of postoperative complications and death. Clinical
interventions that can effectively prevent or address excessive postoperative hemorrhage in cardiac surgery are
likely to have substantial cost-effectiveness potential.
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MExcessive postoperative hemorrhage in cardiac surgery is
a serious complication that is independently associated with
serious postoperative adverse events, including sepsis, acute
respiratory distress syndrome, renal failure, and death.1-5 Ex-
cessive postoperative hemorrhage and its associated risk of
reexploration also place a high demand on hospital resources
in terms of transfusion needs, ventilatory support require-
ments, intensive care support, and manpower require-
ments.5-9 No standard definition of excessive postoperative
hemorrhage exists,10 and there is a lack of solid incidence
data as a result, yet reports in the literature indicate that 3%
to 5%of patients undergoing cardiac surgery require a second
operation to control postoperative hemorrhage.3,4,9,11
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fact known about the exact economic impact of this complica-
tion. To our knowledge, only one group of researchers has
examined the cost of postoperative hemorrhage in cardiac sur-
gery.7,8 In these small case-control US studies, patients with
postoperative hemorrhage required significantly more blood
transfusion and longer intensive care unit (ICU) and hospital
stay. The mean incremental costs of excessive postoperative
hemorrhage, defined as postoperative chest tube drainage
greater than 800 mL during a 4-hour period, was $11,266.8
Knowledge of the economic consequences of excessive
postoperative hemorrhage is a highly essential step in the
efforts to identify potentially cost-effective clinical interven-
tions in cardiac surgery. Avoidance of postoperative hemor-
rhage may reduce morbidity and mortality and reduce the
requirements for hospital resources.12,13 Depending on their
costs, new clinical interventions can either be cost-saving (if
hospital costs savings are greater than the cost of the interven-
tion), cost-effective (if the incremental costs of using the clin-
ical intervention is reasonable in regards to the clinical benefits
obtained), or cost-enhancing (if the clinical intervention in-
duces higher hospital costs without any clinical benefit). By
quantifying the economic consequences of excessive postop-
erative hemorrhage, it is possible to evaluate the cost-effective-
ness of clinical interventions to avoid excessive hemorrhage
and hopefully optimize the clinical pathway and outcome.ardiovascular Surgery c Volume 138, Number 3 687
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AMI ¼ acute myocardial infarction
CPB ¼ cardiopulmonary bypass
ICU ¼ intensive care unit
TISS-28 ¼ Therapeutic Intervention Scoring
System
The objective of this study is to quantify the incremental av-
erage hospital costs of excessive postoperative hemorrhage
in cardiac surgery in Germany.
METHODS
Definition of Excessive Postoperative Hemorrhage
We defined excessive postoperative hemorrhage as postoperative bleed-
ing into drains placed in the cardiothoracic cavity after admission to the
ICU. Drainage loss was assessed on an hourly basis after completion of
a 30-minute stabilization period. Drainage loss was defined by at least
1 of the following criteria: (1) 200 mL/h in any 1 hour or part thereof,
or (2)2 mL/kg/h for 2 consecutive hours in the first 6 hours after surgery.
Blood loss during the stabilization period was not included in the definition
of the volume criteria as such loss may be due to postural changes when
transferring the patient from the operating room table to the bed or due to
fluid in the pleural or mediastinal cavity, which may have arisen from the
rinsing with water as an attempt to achieve surgical hemostasis. Information
on hourly bleeding was manually extracted from patient records.
Study Population
The Quality Assurance Database in Germany was established in 2001 to
enhance the quality of all surgical interventions performed in the country.All
cardiac surgery units submit annually a standard set of perioperative data re-
lated to all cardiac surgeries performed. In this study, we obtained data for all
patients aged 18þhaving cardiac surgery at the Heart Center of the Klinikum
Augsburg between January 1, 2006 and December 31, 2006. A total of 1233
patients had cardiac surgerywith cardiopulmonary bypass (CPB) at this hos-
pital that year, and after adjusting for inconsistent data, 1188 patients were
eligible to be included in the study. The Institutional Review Board at Klini-
kum Augsburg approved the study (IRB No. 45033).
Data Collection and Cost Assessment
All relevant data on patient characteristics, surgical care, postoperative
care, and clinical outcomes were collected. All postoperative complications
identified were defined according the National Bundesgescha¨ftsstelle Quali-
ta¨tssicherung gGmbH definitions14 as the Quality Assurance database at
Klinikum Augsburg follows the exact same data structure as the national
Bundesgescha¨ftsstelle Qualita¨tssicherung gGmbH database. We calculated
treatment costs for each patient according to resources consumed during
surgery, resources consumed in ICU, and resources consumed in general
ward before hospital discharge. Specifically, we investigated costs by
type of surgery, surgery time, need and time for hemofiltration, intra-aortic
balloon pump, and extracorporeal membrane oxygenation, incidence of re-
exploration for bleeding and other causes, blood transfusion (all types of
products), admission and length of stay in ICU, ventilatory support require-
ments, manpower requirements in ICU as measured by the Therapeutic In-
tervention Scoring System (TISS-28) score, and length of stay in hospital
after discharge from ICU. Data on unit costs were obtained for all relevant
resource use (Appendix 1). Treatment costs were determined on a patient-
level basis by multiplying the individual resource use with the relevant
unit costs. Overhead costs were not specifically accounted for in this anal-688 The Journal of Thoracic and Cardiovascular Suysis, yet they were captured in the cost for ICU and general ward stay (cost
per day).
Statistical Analysis
First, we examined the demographic and clinical characteristics (pre- and
postoperative) of the study population and the acute treatment provided in
the total cohort and separately in patients with and without postoperative
hemorrhage. Noncontinuous variables were compared using the chi-square
test or Fisher exact test, as appropriate. Continuous variables were described
by the mean  standard deviation. The Mann-Whitney rank-sum test was
used to compare medians where a normality test failed. Second, we com-
puted treatment costs for every patient and calculated average treatment
costs for the total study population. The average costs of treatment was an-
alyzed according to the main components of care and the unadjusted differ-
ences in costs between patients with and without excessive postoperative
hemorrhage were analyzed. Third, to identify the incremental costs of exces-
sive postoperative hemorrhage while adjusting for potential confounding
factors, we undertook a multivariate regression analysis using ordinary least
squares. We adjusted for all pre- and intraoperative characteristics that
potentially could explain differences in treatment costs between patients
with and without excessive postoperative hemorrhage. All statistical analy-
ses were performed using LimDep Software, Version 3.0.5, 2003.
RESULTS
Of the 1188 patients with complete data, 57.2% had pri-
mary coronary artery bypass grafting surgery; 18.3%, single
valve surgery (repair or replacement); 22%, both types of
surgeries; and 2.5%, other types ofmajor cardiac surgery, in-
cluding aortic root replacement. A total of 76 patients (6.4%)
were identified with excessive postoperative hemorrhage af-
ter applying the criteria for hemorrhage in the ICU. The pre-
operative characteristics of patients are shown in Table 1.
Seventy-two percent (n ¼ 865) of the patients were men,
and the mean age was 67 years (11). Forty-nine percent
were admitted with a primary diagnosis of acute myocardial
infarction (AMI), and 24% were admitted with valve disor-
der. Patient with excessive postoperative hemorrhage were
significantly more likely to have preoperative renal dysfunc-
tion (P¼ .0229), liver disease (P¼ .0458), preoperative coa-
gulopathy (P¼ .0207), and emergency surgery (P¼ .0416).
Duration of surgery (P ¼ .0012) and time on CPB (P ¼
.0015) were also significantly longer in patients with exces-
sive postoperative hemorrhage (Table 2), and they were sig-
nificantly more likely to require hemofiltration (P ¼ .001)
and intra-aortic balloon pump support (P ¼ .0488) and to
experience intraoperative complications (P ¼ .0024).
Differences in postoperative characteristics between pa-
tients with and without excessive postoperative hemorrhage
are shown in Table 3. Excessive postoperative hemorrhage
was significantly associated with postoperative complica-
tions, including stroke (P ¼ .0002), low cardiac output
(P ¼ .0240), pleural effusion (P< .0001), postoperative
pericardial tamponade (P ¼ .0013), and coagulopathy
(P< .0001). Patients with excessive postoperative hemor-
rhage were also significantly more likely to require pro-
longed ventilation after surgery (P< .0001), re-exploration
for bleeding (P< .0001) and other causes (P ¼ .0075),rgery c September 2009
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Variable Total cohort (n ¼ 1188) No bleeding (n ¼ 1112) Bleeding (n ¼ 76) P value, bleeding vs no bleeding
All patients (n,%) 1,188 1,112 76 (6.4%) —
Mean age, y (mean  SD) 67.2 (10.8) 67.2 (10.8) 66.9 (12.1) .4950
Male sex (n,%) 865 (72.8%) 803 (72.2%) 62 (81.6%) .0710
Mean BMI (mean  SD) 27.6 (4.9) 27.6 (4.9) 27.1 (4.9) .347
Admitting diagnosis (n,%)
Unstable angina 79 (6.6%) 75 (6.7%) 4 (5.3%) .6576
Acute myocardial infarction 583 (49.1%) 551 (49.6%) 32 (42.1%) .2119
Valve disorder 290 (24.4%) 270 (36.8%) 20 (26.3%) .6800
Other underlying disorder 236 (19.9%) 216 (19.7%) 20 (26.3%) .1560
Preoperative antithrombotics
(aspirin and clopidogrel)
663 (55.8%) 623 (56.0%) 40 (52.6%) .5656
Preoperative anticoagulants (n,%) 263 (22.1%) 246 (22.1%) 17 (22.4%) .9426
IV nitrate (n,%) 55 (4.6%) 52 (4.7%) 3 (3.9%) .8232
IV inotrope (n,%) 22 (1.9%) 19 (1.7%) 3 (3.9%) .2087
Preoperative HCT (mean  SD) 40.0 (5.14) 40.1 (5.12) 39.1 (5.2) .1083
Preoperative renal dysfunction (n,%) 302 (25.4%) 274 (24.6%) 28 (36.8%) .0229
Preoperative creatinine (mg/dL) 1.15 (0.6) 1.13 (0.6) 1.3 (0.6) .013
Comorbidities (n,%)
Liver disease 61 (5.1%) 53 (4.8%) 8 (10.5%) .0485
GI disease 68 (5.7%) 65 (5.8%) 3 (3.9%) .5269
Endocrine disease 85 (7.2%) 76 (6.8%) 9 (11.8%) .1243
Malignancy 35 (2.9%) 33 (3.0%) 2 (2.6%) .9406
Other 334 (28.1%) 317 (28.5% 17 (22.4%) .2510
Acute infections 83 (7%) 78 (7.0%) 5 (6.6%) .9316
Preoperative coagulopathy 17 (1.4%) 13 (1.2%) 4 (5.3%) .0207
Previous OR (n,%) 87 (7.3%) 77 (6.9%) 10 (13.2%) .0631
Urgency (n,%)
Elective 450 (37.9%) 431 (38.8%) 19 (25.0%) .0152
Urgent 485 (40.8%) 452 (40.6%) 33 (43.4%) .6333
Emergent 241 (20.3%) 220 (19.8%) 21 (27.6%) .1107
Emergency/resuscitation 12 (1.0%) 9 (0.8%) 3 (3.9%) .0416
BMI, Body mass index; CABG, coronary artery bypass graft; HCT, hematocrit; IV, intravenous; GI, gastrointestinal; OR, operations; SD, standard deviation.P
Mtransfusion of all blood products (P<.0001), stay in the ICU
for more than 72 hours (P< .0001), and more manpower
while in the ICU as measured by the TISS-28 score (P<
.0001). In total, 22.4% of the patients with excessive postop-
erative hemorrhage were dead at 30 days after cardiac sur-
gery, which was significantly higher than the 5.5%
mortality rate observed in patients without excessive hemor-
rhage (P< .0001).
Univariate analysis of the key cost drivers in cardiac
surgery revealed significantly higher costs in patients with
excessive postoperative hemorrhage (Table 4). The cost ofICU stay dominated overall costs (51%), followed by the
cost of manpower requirements (TISS-28 score) (28%),
surgery (27%), and length of stay in general ward (10%).
The cost of reexploration (3%) and blood transfusion
(4%) contributed little to the overall hospital costs. Without
adjustment for potential confounding factors, the average
hospital costs of patients with and without excessive postop-
erative hemorrhage were V15,404 (8986) and V8027
(7557), respectively. Adjustment for relevant confounders
in multivariate analysis indicated a significant incremental
cost of excessive postoperative hemorrhage of V6251TABLE 2. Intraoperative characteristics of patient cohort
Surgery-related covariates Total cohort (n ¼ 1188) No bleeding (n ¼ 1112) Bleeding (n ¼ 76) P value, bleeding vs no bleeding
Surgery time (min) 172.8 (50.2) 170.6 (46.2) 205.2 (84.7) .0012
CPB duration (min) 78.3 (33.3) 77.1 (31.5) 96.3 (50.8) .0015
Body temperature 34.8 (2.9) 34.9 (2.8) 33.8 (3.5) .0009
Use of IABP 40 (3.4%) 34 (3.1%) 6 (7.9%) .0488
Any intraoperative complications* 38 (3.2%) 30 (2.7%) 8 (10.5%) .0024
Other intraoperative complications 20 (1.7%) 16 (1.4%) 4 (5.3%) .0410
CPB, Cardiopulmonary bypass; IABP, intra-aortic balloon pump; ECMO, extracorporeal membrane oxygenation. *Intraoperative complications included low cardiac output,
hypoxemia, and other intraoperative complications.
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Variable Total cohort (n ¼ 1188) No bleeding (n ¼ 1112) Bleeding (n ¼ 76) P value, bleeding vs no bleeding
Postoperative complications 75 (6.3%) 60 (5.4%) 15 (19.7%) <.0001
Stroke 58 (4.9%) 46 (4.1%) 12 (15.8%) .0002
Low cardiac output 65 (5.5%) 54 (4.9%) 11 (14.5%) .0240
Pleural effusion 106 (8.9%) 93 (8.4%) 26 (34.2%) <.0001
Tamponade 43 (3.6%) 34 (3.1%) 9 (11.8%) .0013
Coagulopathy 16 (1.3%) 7 (0.6%) 9 (11.8%) <.0001
Postoperative ventilation
>24 h 147 (12.4%) 120 (10.8%) 27 (35.5%) <.0001
Hemofiltration 188 (15.8%) 165 (14.8%) 23 (30.3%) .001
Reexploration 84 (7.1%) 38 (3.4%) 45 (59.2%)
For bleeding 47 (4.0%) 9 (0.8%) 38 (50%) <.0001
For other causes 37 (3.0%) 29 (2.6%) 7 (9.2%) .0075
Postoperative blood
transfusions
463 (39.0%) 388 (34.9%) 64 (84.2%) <.0001
RBC 452 (38.0%) 388 (34.9%) 64 (84.2%) <.0001
FFP 95 (8.0%) 56 (5.0%) 39 (51.3%) <.0001
Platelets 39 (3.3%) 19 (1.7%) 19 (25.0%) <.0001
Units of RBC transfused 1.1 (2.3) 0.9 (1.9) 4.5 (3.8) <.0001
Units FFP transfused 0.5 (2.2) 0.3 (1.6) 4.1 (5.2) <.0001
Mean postoperative blood loss 549 (941) 472 (873) 1,669 (1170) <.0001
LOS ICU
>72 h (n,%) 290 (24.4%) 251 (22.6%) 39 (51.3%) <.0001
Total 4.1 (4.7) 3.1 (5.0) 5.7 (5.3) <.0001
TISS-28 66.9 (69.5) 44.7 (52.8) 85.9 (76.5) <.0001
Mortality 72 (6.1%) 56 (5.0%) 16 (21.1%) <.0001
30-day mortality 78 (6.6%) 61 (5.5%) 17 (22.4%) <.0001
RBC, Red blood cell; FFP, fresh frozen plasma; ICU, intensive care unit; LOS, length of stay; TISS-28, Therapeutic Intervention Scoring System.(95% confidence interval, 4594–7909; Table 5). Using this
adjusted estimate, the average hospital cost of patients with
excessive postoperative hemorrhage was V14,279, all else
equal. In addition to postoperative hemorrhage, the multi-
variate analysis also indicated that preoperative inotrope
use (P ¼ .000), preoperative renal dysfunction (P ¼ .000),
any infection (P ¼ .000), previous operation (P ¼ .0269),
elective (P ¼ .0052) and urgent procedures (P ¼ .000)
were significant independent determinants of hospital costs.
DISCUSSION
The objective of this study was to quantify the incremen-
tal costs of excessive postoperative hemorrhage in cardiacsurgery.We found that patients with excessive postoperative
hemorrhage are significantly more likely to require pro-
longed ventilation after surgery, reexploration for bleeding
and other causes, transfusion of all blood products, stay in
the ICU for more than 72 hours, and more manpower while
in the ICU as measured by the TISS-28 score. Adjusted for
potential confounders, the higher resource requirements of
patients with excessive postoperative hemorrhage resulted
in significantly higher average hospital costs compared
with patients without postoperative hemorrhage.
Our results compare well with those published by Her-
waldt and colleagues7,8 despite differences in the definition
of excessive postoperative hemorrhage. In their case-controlTABLE 4. Univariate analysis of hospital cost (V) for cardiac surgery: effect of postoperative hemorrhage
Cost components All patients (n ¼ 1188) No bleeding (n ¼ 1112) Bleeding (n ¼ 76) P value
Surgery-related* (mean  SD) 2304 (669) 2274 (615) 4018 (1753) <.0001
Postoperative complicationsy (mean  SD) 208 (848) 178 (785) 652 (1429) <.0001
Reexploration for bleeding (mean  SD) 230 (842) 112 (600) 1956 (1635) <.0001
Cost of blood products (mean  SD) 134 (346) 93 (257) 732 (730) <.0001
Cost of total ICU stay (mean  SD) 4370 (6779) 4150 (6699) 7582 (7172) <.0001
Cost by TISS-28 score 2407 (2502) 1609 (1902) 3095 (2754) <.0001
Cost of ward stay 876 (661) 877 (640) 859 (928) .0461
Total cost (mean  SD)z 8499 (7862) 8027 (7557) 15,404 (8986) <.0001
*Based on surgery time and CPB time, postoperative complications include cost for myocardial infarction and stroke. yIntraoperative complications included low cardiac output,
hypoxemia, and other intraoperative complications. zTotal cost should not be summed, represents mean total cost of cost components only.
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Incremental cost Standard error t value P value 95% confidence interval
Constant* 8027.51 1.8696606 4293.565 .000 8023.84–8031.17
Age 11.33 20.415367 0.555 .579 28.69–51.34
Male 995.74 478.70688 2.08 .0375 57.48–1934.01
BMI 69.73 41.987478 1.661 .0968 12.57–152.03
Admitting diagnosis
MI 348.99 849.89334 0.411 .6813 2014.78–1316.80
Valve disorder 57.72 906.06157 0.064 .9492 1718.16–1833.60
Other 202.35 934.87075 0.216 .8286 1630.00–2034.70
Antithrombotics use 9.60 8.3284475 1.153 .2491 6.72–25.92
Preoperative anticoagulants 6.62 4.1160559 1.607 .108 14.68–1.45
IV nitrate 201.64 1003.816 0.201 .8408 2169.12–1765.84
IV inotrope 11,737.56 1630.3749 7.199 .000 8542.02–14,933.09
HCT 0.45 1.577093 0.284 .7765 3.54–2.64
Renal dysfunction 3078.31 508.93187 6.049 .000 2080.81–4075.82
Creatinine 3.42 7.2556871 0.471 .6376 10.80–17.64
Comorbidities
Liver disease 0.98 3.5436956 0.275 .783 5.97–7.92
GI disease 8.43 8.2886632 1.017 .3092 7.82–24.67
Endocrine disease 1.30 5.0370064 0.258 .7964 11.17–8.57
Malignancy 54.66 1245.7818 0.044 .965 2496.40–2387.07
Other comorbidity 0.21 4.0891052 0.05 .96 8.22–7.81
Any infection 3492.79 831.63853 4.2 .000 1862.78–5122.80
Coagulopathy 2.25 2.367213 0.951 .3417 6.89–2.39
Previous operation 1781.62 804.87552 2.214 .0269 204.06–3359.17
Elective 1317.33 471.63121 2.793 .0052 2241.73–392.93
Urgent 2376.88 577.36643 4.117 .000 1245.24–3508.52
Emergent 2047.63 2196.2459 0.932 .3512 6352.27–2257.01
Bleedingy 6251.38 845.60114 7.393 .000 4594.00–7908.76
BMI, Body mass index; MI, myocardial infarction; IV, intravenous; HCT, hematocrit; GI, gastrointestinal. *Average cost for patients without postoperative hemorrhage, all else
equal. yIncremental cost for patients with postoperative hemorrhage.P
Mstudies, excessive postoperative hemorrhage was defined by
either a surrogate for bleeding (reoperation for bleeding
regardless of the amount of blood lost in chest tubes) or by
postoperative chest tube drainage greater than 800 mL dur-
ing a 4-hour period. In the first study,7 the authors found pa-
tients with postoperative chest tube drainage greater than
800 mL to have significantly more blood transfusions and
longer hospital stays than controls. The unadjusted mean dif-
ference in hospital costs was $11,266 (orV7702 when using
current exchange rate), which is very close to the unadjusted
cost difference of V7377 observed in our study. In the sec-
ond study, using a mixture of patients identified with postop-
erative hemorrhage due to the surgery or volume criteria, the
mean difference in hospital costs was substantially smaller
($2945), yet this is likely explained by the difference in
eligibility criteria.
In our study, we found the average incremental (extra)
cost of excessive postoperative hemorrhage to be V6251
per patient. Although this amount may not seem excessive
on a larger scale of health care spending, it is important to
note that this cost estimate only relates to the resources
required during the initial hospitalization. The cost of fol-
low-up care (inpatient and outpatient) may be significant,The Journal of Thoracic and Cin particular in regards to postoperative complications such
as AMI and stroke.15-17 Indeed, the long-term health care
costs associated with AMI and stroke may represent the
majority of the life-costs in AMI and stroke survivors. In ad-
dition, there are the indirect costs of excessive postoperative
hemorrhage in terms of foregone productivity attributable to
premature mortality and morbidity. In gauging the potential
of new clinical interventions to address the cost of excessive
postoperative hemorrhage, the perspective of the assessor is
clearly paramount (eg, hospital, insurance company, or gov-
ernment). However, when the cost of excessive postopera-
tive hemorrhage is considered from a national long-term
perspective, both the direct and indirect costs of the compli-
cation should clearly be evaluated.
The etiology of excessive postoperative hemorrhage in
cardiac surgery is multifactorial and may be related to med-
ications, history of preexisting coagulopathy, surgical proce-
dure, and other unrecognized factors.10 An important aspect
of addressing excessive hemorrhage relates to preopera-
tively identifying patients at risk during or after surgery. In
our study, we found patients with excessive postoperative
hemorrhage to bemore likely to have preoperative renal dys-
function, liver disease, and coagulopathy; to needardiovascular Surgery c Volume 138, Number 3 691
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gery time, including time spent on the CPB. In other studies,
increased age, nonelective surgery, low body surface area,
prolonged CPB time (>150 minutes), combined intracardiac
and coronary bypass graft surgery, number of bypass grafts
(5), reoperative surgery, and preoperative antiplatelet
agents have been consistently identified as risk factors for
postoperative hemorrhage.4,18,19 Though more research on
the risk factors for excessive postoperative hemorrhage is
needed,8 it is clear that, from a cost-effectiveness perspec-
tive, clinical interventions that can either prevent or effec-
tively address postoperative hemorrhage are likely to be
cost-effective. In our study, we observed a mortality rate
of 22.4% in patients with excessive postoperative hemor-
rhage compared with 5.5% in patients without this compli-
cation. At an average incremental cost of V6251, the
difference in survival implies an average V36,771 per life
lost as a result of this complication. In other words, patients
with excessive postoperative hemorrhage are more expen-
sive and more likely to die than those without excessive
postoperative hemorrhage. Even without taking the long-
term costs (direct or indirect) of excessive postoperative
hemorrhage into account, there seems ample economic
potential for addressing this critical clinical complication.
Our study has a number of limitations. First, our estimate
of the incremental costs of excessive postoperative hemor-
rhage depends in part on the unit cost associated with the
extra resources required to treat this complication. Unit costs
are inherently idiosyncratic for the health care system in
which they are retrieved, and hence it is questionable to
what extent our estimation can be generalized to other health
care systems outside of Germany. Second, we did not
include the long-term costs (direct or indirect) associated
with excessive postoperative hemorrhage. In patients with
thromboembolic complications such as AMI and stroke,
these costs are likely to be substantial. Additionally, the
high mortality rate associated with excessive postoperative
hemorrhage indicates that there are substantial societal losses
associated with this complication relating to lost productiv-
ity. Future research should aim to quantify the long-term eco-
nomic implications of excessive postoperative hemorrhage
and its associated clinical outcomes. Third, our assessment
did not take into account the impact of excessive postopera-
tive hemorrhage on quality of life. For the patients left with
significant functional disabilities due to stroke, the nonmon-
etary cost to survivors and their family can be substantial.
CONCLUSIONS
We find the average hospital costs of excessive postoper-
ative hemorrhage in cardiac surgery to be substantial and
associated with a significant risk of postoperative complica-
tions and death. Clinical interventions that can effectively
prevent or address excessive postoperative hemorrhage in692 The Journal of Thoracic and Cardiovascular Sucardiac surgery are likely to have substantial cost-effective-
ness potential.
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Christensen et al Perioperative ManagementAPPENDIX 1. Unit cost by hospital resource
Cost component Cost (V) Source/reference
Surgery
Surgery time (per minute) 13.33 OP Management, 2007 (V800 per hour)
Hemofiltration (run time per day) 943.00 Herzchirurgie, Bad Krozingen, 200720
ECMO 5736.00 Herzchirurgie, Bad Krozingen, 200720
IABP 1283.00 Herzchirurgie, Bad Krozingen, 200720
Recovery
Cost for reexploration 3305.00 Herzchirurgie, Bad Krozingen, 200720
Transfusion of RBC (cost per unit) 75.00 Harig et al., 200721
Transfusion of FFP (cost per unit) 67.00 Harig et al., 200721
Transfusion of platelets (cost per unit) 467.00 Harig et al., 200721
ICU cost per day (24 h) 1334.00 Graf et al., 200222
Cost per ward day 62.00 Herzchirurgie, Bad Krozingen, 200720
TISS-28 (cost per point/score) 36.00 Graf et al., 200222
ECMO, Extracorporeal membrane oxygenation; IABP, intra-aortic balloon pump; RBC, red blood cells; FFP, fresh frozen platelets; ICU, intensive care unit; TISS-28, Therapeutic
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